Lindahl acted as legal advisor to Corline Biomedical in connection with a license agreement with the California-based company Imperative Care, which develops next generation of stroke care. The agreement concerns license rights to Corline's technology and delivery of products surface-treated (coated) with Corline's antithrombotic surface coating CHS™.
Through the agreement, Imperative Care is given the exclusive right to use CHS™ in all types of neurovascular products given a certain level of compensation. Corline undertakes to supply CHS™-coated products according to defined specifications, but also to assist in further development and market registration of the current product. In addition, Corline will participate in the development of additional CHS™-coated products within the indication area. These products have the potential to generate revenue for Corline of approximately SEK 150 million per year and a total of more than SEK 1 billion.
Lindahl's team consisted of Hugo Norlén and Erika Svensson.
Corline's press release (in Swedish) is available here.
